All-oral interferon-free treatments:The end of hepatitis C virus story,the dream and the reality

被引：0

作者：

Luigi E Adinolfi ^{[1
]}

Barbara Guerrera ^{[1
]}

机构：

[1] Department of Medical,Surgical,Neurological,Geriatric and Metabolic Sciences,Second University of Naples

来源：

World Journal of Hepatology | 2015年 / 22期

关键词：

Sofosbuvir; Simeprevir; New-oral hepatitis C virus treatments; Paritaprevir; Dasabuvir; Daclatasvir; Ledipasvir; Ombitasvir;

D O I：

暂无

中图分类号：

R512.63 [];

学科分类号：

100401 ;

摘要：

The year 2014 marked the beginning of the end of the interferon era and the triumph of the all-oral interferon-free regimens for treatment of hepatitis C virus(HCV) infection. These innovative therapies are safe and yield a cure rate of over 90%. The scientifichepatology community is euphoric about the possibility of elimination and even eradication of HCV infection. However,the current high cost of the new all-oral regimens allows access to treatment only for a restricted number of HCV-infected patients. In addition,many other conditions such as modality of access and delivery of care,inadequate knowledge of HCV epidemiology and political commitments to be undertaken,hamper the fulfillment of the dream to eliminate the virus. Since,such conditions are not impossible to overcome,a global urgent effort must be made to allow a widespread access to the new treatments which will permit in the next years to avoid million of HCV-related deaths.

引用

页码：2363 / 2368

页数：6

共 14 条

[1] Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013[J] . The Lancet . 2015 (9963)
[2] All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study[J] . David R. Nelson,James N. Cooper,Jacob P. Lalezari,Eric Lawitz,Paul J. Pockros,Norman Gitlin,Bradley F. Freilich,Ziad H. Younes,William Harlan,Reem Ghalib,Godson Oguchi,Paul J. Thuluvath,Grisell Ortiz‐Lasanta,Mordechai Rabinovitz,David Bernstein,Michael Bennett,Trevor Hawkins,Natarajan Ravendhran,Aasim M. Sheikh,Peter Varunok,Kris V. Kowdley,Delphine Hen
[3] Sofosbuvir With Peginterferon-Ribavirin for 12 Weeks in Previously Treated Patients With Hepatitis C Genotype 2 or 3 and Cirrhosis
Lawitz, Eric
Poordad, Fred
Brainard, Diana M.
Hyland, Robert H.
An, Di
Dvory-Sobol, Hadas
Symonds, William T.
McHutchison, John G.
Membreno, Fernando E.
[J]. HEPATOLOGY, 2015, 61 (03) : 769 - 775
[4] Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kowdley, Kris V.
Gordon, Stuart C.
Reddy, K. Rajender
Rossaro, Lorenzo
Bernstein, David E.
Lawitz, Eric
Shiffman, Mitchell L.
Schiff, Eugene
Ghalib, Reem
Ryan, Michael
Rustgi, Vinod
Chojkier, Mario
Herring, Robert
Di Bisceglie, Adrian M.
Pockros, Paul J.
Subramanian, G. Mani
An, Di
Svarovskaia, Evguenia
Hyland, Robert H.
Pang, Phillip S.
Symonds, William T.
McHutchison, John G.
Muir, Andrew J.
Pound, David
Fried, Michael W.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) : 1879 - 1888
[5] Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Afdhal, Nezam
Zeuzem, Stefan
Kwo, Paul
Chojkier, Mario
Gitlin, Norman
Puoti, Massimo
Romero-Gomez, Manuel
Zarski, Jean-Pierre
Agarwal, Kosh
Buggisch, Peter
Foster, Graham R.
Braeu, Norbert
Buti, Maria
Jacobson, Ira M.
Subramanian, G. Mani
Ding, Xiao
Mo, Hongmei
Yang, Jenny C.
Pang, Phillip S.
Symonds, William T.
McHutchison, John G.
Muir, Andrew J.
Mangia, Alessandra
Marcellin, Patrick
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (20) : 1889 - 1898
[6] Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial[J] . Michael Manns,Patrick Marcellin,Fred Poordad,Evaldo Stanislau Affonso de Araujo,Maria Buti,Yves Horsmans,Ewa Janczewska,Federico Villamil,Jane Scott,Monika Peeters,Oliver Lenz,Sivi Ouwerkerk-Mahadevan,Guy De La Rosa,Ronald Kalmeijer,Rekha Sinha,Maria Beumont-Mauviel.The Lancet
[7] Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial[J] . Ira M Jacobson,Gregory J Dore,Graham R Foster,Michael W Fried,Monica Radu,Vladimir V Rafalsky,Larysa Moroz,Antonio Craxi,Monika Peeters,Oliver Lenz,Sivi Ouwerkerk-Mahadevan,Guy De La Rosa,Ronald Kalmeijer,Jane Scott,Rekha Sinha,Maria Beumont-Mauviel.The Lancet . 2014 (9941)
[8] Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study[J] . Eric Lawitz,Mark S Sulkowski,Reem Ghalib,Maribel Rodriguez-Torres,Zobair M Younossi,Ana Corregidor,Edwin DeJesus,Brian Pearlman,Mordechai Rabinovitz,Norman Gitlin,Joseph K Lim,Paul J Pockros,John D Scott,Bart Fevery,Tom Lambrecht,Sivi Ouwerkerk-Mahadevan,Katleen Ca
[9] Expanding Primary Care Capacity to Treat Hepatitis C Virus Infection Through an Evidence-Based Care Model - Arizona and Utah, 2012-2014[J] . Mitruka,Kiren,Thornton,Karla,Cusick,Susanne,Orme,Christina,Moore,Ann,Manch,Richard A,Box,Terry,Carroll,Christie,Holtzman,Deborah,Ward,John W.MMWR. Morbidity and Mortality Weekly Report . 2014 (18)
[10] ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-experienced Patients with HCV Genotype 1b Infection[J] . Pietro Andreone,Massimo G. Colombo,Jeffrey V. Enejosa,Iftihar Koksal,Peter Ferenci,Andreas Maieron,Beat Müllhaupt,Yves Horsmans,Ola Weiland,Henk W. Reesink,Lino Rodrigues,Yiran B. Hu,Thomas Podsadecki,Barry Bernstein.Gastroenterology . 2014

← 1 2 →